695 filings
Page 2 of 35
4
4uxxb5qrwlbo
2 Feb 24
ZEVRA THERAPEUTICS / Neil F. McFarlane ownership change
8:10pm
4
e38ns8nz
2 Feb 24
ZEVRA THERAPEUTICS / Alvin Shih ownership change
8:08pm
3
huwabd7nm5 ahpf7rmg
2 Feb 24
ZEVRA THERAPEUTICS / Alvin Shih ownership change
7:13am
SC 13G
1ptvu 4yz
29 Jan 24
ZEVRA THERAPEUTICS / BlackRock ownership change
5:25pm
8-K
hqhvdmh6dvevxiv3rly
23 Jan 24
Departure of Directors or Certain Officers
7:37am
8-K
su3x9cl3cwwvv8z
8 Jan 24
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8:03am
8-K
pb1 wrh42st1yitfn98d
27 Dec 23
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
7:48am
424B5
tb7926y
21 Nov 23
Prospectus supplement for primary offering
7:40pm
8-K
xxz219kp7rzvzw
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
mmt4dvb6vmx0holj3ie
7 Nov 23
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial
7:25am
425
u60sflf7u7 2rnz39qme
30 Oct 23
Business combination disclosure
4:42pm
8-K
hg064 lpk
30 Oct 23
Other Events
8:25am
4
apuz8 3uqf67
11 Oct 23
ZEVRA THERAPEUTICS / Neil F. McFarlane ownership change
4:33pm
EFFECT
23ye08ulvz
11 Oct 23
Notice of effectiveness
12:15am
3
hv53a9l
10 Oct 23
ZEVRA THERAPEUTICS / Neil F. McFarlane ownership change
8:20pm
8-K
5t3nvq6 5wkcek
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
424B3
qu4i ed2ogwyafanlrx
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
m8s8x0m6
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
CORRESP
iqe0t57
6 Oct 23
Correspondence with SEC
12:00am